Loading
PRTX007 is a small-molecule inhibitor from Primmune Therapeutics, Inc., in registered phase 2 trials for melanoma.
PRTX007 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Primmune Therapeutics, Inc., in melanoma. Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording.
1.PRTX007 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"PRTX007" OR ABSTRACT:"PRTX007") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRTX007, not a curated reading list.
Shares Melanoma and the tags pipeline, registry-only.
Shares Melanoma and the tags pipeline, registry-only.
Shares Melanoma and the tags pipeline, registry-only.
Shares Melanoma and the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.